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Chemotherapy. METHODS: An analysis of the IMS Health
ONCO Combined, LMPH, EHPP, GERS databases allowed
identifying the anti-emetic schemes used in this indication in
2002, to draw up the market trend in ambulatory care and in
hospital, and to determine the cost of corresponding consump-
tion. A budget impact model was built over 4 years with several
scenarii. The results are reported for 10,000 HEC cycles with a
reduction in the use of the cisplatin of 5% per year, a 10%, 15%,
20%, 25% penetration rate of aprepitant, and a substitution rate
in the delayed phase increasing from 30% to 90% over the
period. RESULTS: The market share of 5-HT3 receptor antago-
nists was equal to 76% of the HEC market in 2002. In ambu-
latory care, the average cost of setrons in acute phase d1 and
both in acute and delayed phases amounts respectively €26.90
and €111.25 per chemotherapy cycle. In hospital the corre-
sponding ﬁgures are €33.02 and €147.50. The antiemetic treat-
ment cost without aprepitant rises to €774,000 the ﬁrst year 
and to €664,000 the fourth year. The net budget impact due to
the introduction of aprepitant is €46,000 the ﬁrst year and
€41,000 the fourth year, i.e. less than 6% each year. In ambula-
tory care, this differential is €23,000 the ﬁrst year and becomes
nearly null cost over the four years. CONCLUSION: The 
overcost generated by the use of aprepitant is small for the
French sickness funds compared to the overall antiemetic 
treatment cost.
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OBJECTIVES: The aim of this study was to estimate costs of
care associated with metastatic colorectal cancer (MCCR) in
current clinical practice and the potential impact on the Spanish
health care budget of cetuximab prescription to patients with
MCCR. METHODS: In order to describe treatment patterns and
to analyse costs of MCCR, a cost of care treatment model was
constructed. The economic impact of cetuximab was estimated
by means of a treatment model for third-line use of the cetux-
imab combination after second-line irinotecan failure. Treatment
patterns were obtained from questionnaires ﬁlled out by 14
Spanish hospitals and from an advisory board of 5 clinical
experts. Treatment algorithms were constructed by using Tree
Age Data Pro software. In order to estimate the unit costs, Diag-
nostic Related Groups were used for inpatient services, while
outpatient services were calculated on daily based rates. Unit
costs were obtained from national databases (€2004). The treat-
ment costs were calculated from the perspective of the Spanish
National Health System. The incidence of MCCR was obtained
from literature review. RESULTS: For a population of 10,350
patients with MCCR in Spain, the total cost (pharmacological
and medical costs) was estimated in €151 million. In that sce-
nario, the cost of care of patients at third-line therapy that had
failed to irinotecan therapy amounted €1.5 million. With the
introduction of cetuximab after second-line irinotecan failure, a
maximum of 193 patients were estimated to be eligible for the
new drug. In this scenario, the total cost of the third-line therapy
would come to €4.7 million. CONCLUSIONS: Cetuximab in
combination with irinotecan is the only third-line therapy indi-
cated in MCCR after irinotecan failure. If the eligible patients in
third-line therapy received cetuximab and irinotecan instead of
current clinical practice, the economic impact of substitution
would amount €3.2 million.
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OBJECTIVES: To evaluate direct treatment cost associated with
pegylated liposomal doxorubicin hydrochloride (PLD) and
topotecan used as second line therapies for ovarian cancer in
Poland. METHODS: The literature review showed topotecan
and PLD have similar efﬁcacy in platinum-refractory or platinum
resistant advanced ovarian cancer but different adverse events
proﬁle. The cost-minimization analysis was performed from the
payer’s perspective. Only direct medical costs (i.e. drug acquisi-
tion costs, drug administration costs and managing adverse
events costs) were included. Based on epidemiological data bud-
getary impact of PLD treatment in Poland was estimated.
RESULTS: The acquisition and drug administration costs were
estimated at €12,448 and €6935 for PLD and topotecan, while
cost of managing adverse events at €134 and €1234 for PLD and
topotekan, respectively. The total cost per patient summed up to
€12,882 for PLD and €8169 for topotecan. 38% reduction in
acquisition cost of PLD would balance topotecan associated
costs. Epidemiological data indicated 985 platinum-resistant or
platinum-refractory ovarian cancer patients in Poland were eli-
gible annually for treatment with PLD, thus additional cost could
be estimated at €4.64 million. CONCLUSIONS: PLD represents
attractive treatment strategy in second line therapy of platinum-
resistant or platinum-refractory ovarian cancer, although acqui-
sition cost reduction is necessary were compared to topotecan in
Polish settings.
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The clinical study phase III 071 has showed the new antiemetic
Aprepitant in association with a standard therapy (corticosteroid
plus a 5-HT3 receptor antagonist) increases signiﬁcantly the
complete response (no vomiting and no rescue treatment) by
more than 10 points compared to the standard therapy used in
MEC. OBJECTIVES: To evaluate the budget impact implied by
the introduction of this new antiemetic on the French sickness
funds. METHODS: The MEC were deﬁned according to the rec-
ommendations of the Multinational Association of Supportive
Care in Cancer (2004). A sample of patients was extracted from
the ONCO IMS 2004 database. The inclusion criteria used were:
to receive a MEC in association with an antiemetic one con-
taining a corticosteroid and a 5-HT3 receptor antagonist and to
have this treatment during the acute and delayed periods. Prices
of the antiemetic treatments were taken from the GERS 2004
database. A budget impact model was implemented over a period
of four years, based on a stable population and on different pen-
etration and substitution rates of Aprepitant. RESULTS: The
results are reported for 10,000 MEC cycles associated to the
standard therapy. The penetration and substitution rates of
Aprepitant increase over the period from 10% to 25% and from
70% to 95%, respectively. In 2004, the treatment cost is
€466,000. The introduction of Aprepitant increases the cost of
the acute phase but decreases it in the delayed one. In the ambu-
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latory care sector the cost decreases over the four years. Every
year the net budget impact due to Aprepitant is less than 3%.
The fourth year, the treatment cost with Aprepitant is equal to
€478,000. CONCLUSION: The additional costs caused by the
introduction of Aprepitant seem fair compared to the gain in
terms of complete control of vomiting.
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OBJECTIVES: To evaluate the economic impact of trastuzumab
treatment in Metastatic Breast Cancer (MBC). Trastuzumab
therapy is initiated in MBC patients over-expressing HER2. The
product is licensed in monotherapy for patients pre-treated with
anthracyclines and taxanes, or associated with paclitaxel for
patients pre-treated by anthracyclines. METHODS: HERMES is
a phase IV multicentric prospective study funded by the French
ministry of health, evaluating the clinical, biochemical and phar-
maco-economic aspect of trastuzumab treatment on MBC.
HER2 status was determined by Immuno-histochemistry or
FISH methods and H-ECD (HER2 Extra-Cellular Domain)
status by ELISA technique. Only HER2 3+ or 2+ and FISH+
patients received treatment. Four protocols were administered:
trastuzumab + paclitaxel weekly (TP1) or three weekly (TP3) and
trastuzumab weekly (T1) or three weekly (T3). Responses were
evaluated according to RECIST criteria then compared to H-
ECD levels. Treatment costs were calculated by adding DGR
costs (2004) and onerous drug reimbursed over DGRs.
RESULTS: In a 3-years period, 120 patients were pre-included
and 88 included. In intention to treat there were 62 TP1, 25 TP3,
and 1 T1. Time to Treatment Failure is 30 weeks [25–35]. 81
patients stopped treatment: 67% for progression, 16% for
cardiac toxicities. Overall survival is 60 weeks [48–80]. Time to
Progression is 34 weeks [27–43]. After 2 months, on 27 patients,
relative risk of progression is of 2.2 for patients with H-ECD
increase. On 22 patients with H-ECD diminution, 20 were
responding to treatment. Overall patient management cost is of
€4,178,000. Average pre-inclusion screening cost is of €829 per
patient. Average treatment cost on 36 weeks reaches €46,345 per
patient including 72% for drug acquisition, 23% for adminis-
tration, 1% for laboratory assessments, 3% for cardiac assess-
ment, 1% for tumour volume assessment. CONCLUSIONS:
From an economic perspective, HER2 assays are cost effective:
they are less expensive than cytotoxic and/or trastuzumab 
treatments.
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OBJECTIVES: To describe treatment patterns and determine
direct medical costs of initiating transdermal opioid systems in
cancer patients with moderate or severe malignant pain. The
study was conducted to test the feasibility of a pharmacoeco-
nomic investigation in the selected patient group. Direct medical
costs per patient and hospital day were calculated from hospital
provider perspective. METHODS: Observational, prospective
cross-sectional study in six units (wards, day clinics) of a uni-
versity hospital. A four-week observation period started with ini-
tiation of the transdermal opioid therapy. Data were obtained
from medical charts and patient diaries. Costs for hospital stay
were only included when pain therapy was the only reason 
for hospital admission. RESULTS: Twenty-eight consecutive
patients with solid tumours were evaluated (gastrointestinal
(39%), urologic (25%), thoracic (14%), CUP (21%). Twelve
patients completed diaries. Participants had a mean age of 61.5
years (range: 38–81), 71% were female and 29% were opioid-
naiv. Six patients died during the observation period. In 71%,
selected doses were in accordance with conversion rates given by
the manufacturers. Mean patch wearing-time was 3.1 days
(range: 2.5–3.6). Average length of stay from ﬁrst patch appli-
cation to hospital discharge was 5.7 days. 39% of the patients
received anti-emetic prophylaxis or treatment and 29% laxatives
to manage opioid side-effects. From hospital provider perspec-
tive mean direct costs were €54 per patient per day. Costs for
hospital stay accounted for the largest portion (€46, 85%). Costs
of pain therapy averaged out €8 (15%), €4 (42%) was analgesic
costs and €4 (51%) application costs. Daily adverse-event man-
agement accounted for €1 per patient. CONCLUSIONS: Costs
for the hospital stay to initiate transdermal opioid therapy were
the major cost driver from hospital provider perspective.
Although constipation and emesis prophylaxis is recommended
by pain management guidelines, in clinical practice a substantial
portion of patients didn’t receive adequate prophylaxis.
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OBJECTIVES: To compare costs of intravenous versus intra-
venous-oral application of cisplatin-etoposide (PE) and cisplatin-
vinorelbine (PN) recommended in NSCLC treatment in Poland.
METHODS: The data of medical resources consumed were col-
lected retrospectively in three major oncology centers in Poland;
among patients with advanced NSCLC (stage IIIb and IV),
treated with intravenous regimen of PE or PN. The payers per-
spective were used and direct medical cost were assessed. All
medical care consumption in intravenous regimen was estimated
from the patients’ medical chart and the information of costs
were derived from the medical valuation system used by
National Fund of Health in 2005. All cost were in polish zloty
(in 2005: 1$ = 3.35 zloty). The resources consumption in com-
bined intravenous-oral regimen was simulated basing on thera-
peutic guidelines of oral regimen of analyzed chemotherapy. We
assume that patient was given intravenous therapy on 1st day
(in both schemes) and oral dose instead of intravenous the fol-
lowing days. Such combination let to reduce the number of hos-
pitalizations due to cytostatics application. RESULTS: The total
costs of PN scheme in intravenous and combined regimen for
one patient was the same and amount to ZL23,416, which
means the savings due to hospitalization were compensate by
increased dose of oral vinorelbine. Despite the increased dose of
oral etoposide the 1228zl difference between intravenous and
combined application was found in PE scheme. The total costs
of treating NSCLC using intravenous and combined PE regimen
were 12,660zl and 11,432zl respectively. CONCLUSIONS: Our
analysis showed that both combinations of intravenous-oral
chemotherapy could be considered as alternatives for intra-
venous regimens.
